Peginterferon-α-2b/ribavirin
1
Reactions 1128 - 18 Nov 2006 S Peginterferon-α-2b/ribavirin Crohn’s disease: case report A 39-year-old woman developed Crohn’s disease during treatment with peginterferon-α-2b plus ribavirin for hepatitis C virus infection. The woman, who was coinfected with HIV infection, started receiving peginterferon-α-2b 180 µg/week plus ribavirin 800 mg/day; her peginterferon-α-2b dose was progressively reduced to 90 µg/week due to severe neutropenia. Three months later, she was admitted with abdominal pain, fever and melena. Blood tests revealed anaemia and a C-reactive protein level of 90 mg/dL (normal < 5). Her CD4+ cell count was reduced to 275 cells/µL. Physical examination showed an axillary temperature of 39°C and mild abdominal pain. The woman started receiving IV ciprofloxacin and metronidazole soon after admission. A colonoscopy 3 days later revealed inflammatory features with aftous reactions and necrotic regions 60cm from the anus. Histological examination revealed epithelial mucosal erosions, with marked chronic and acute inflammation and muscolaris mucosae involvement, suggestive of inflammatory bowel disease. She received mesalazine and her clinical symptoms and biochemical parameters recovered rapidly. Over the next 3 months, she experienced no other symptoms of inflammatory bowel disease. Bongiovanni M, et al. Crohn’s disease onset in an HIV/hepatitis C virus co- infected woman taking pegylated interferon alpha-2b plus ribavirin. AIDS 20 (Suppl.): 1989-1990, No. 15, 3 Oct 2006 - Italy 801051210 1 Reactions 18 Nov 2006 No. 1128 0114-9954/10/1128-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Peginterferon-α-2b/ribavirin
Reactions 1128 - 18 Nov 2006
SPeginterferon-α-2b/ribavirin
Crohn’s disease: case reportA 39-year-old woman developed Crohn’s disease during
treatment with peginterferon-α-2b plus ribavirin for hepatitis Cvirus infection.
The woman, who was coinfected with HIV infection, startedreceiving peginterferon-α-2b 180 µg/week plus ribavirin800 mg/day; her peginterferon-α-2b dose was progressivelyreduced to 90 µg/week due to severe neutropenia. Threemonths later, she was admitted with abdominal pain, fever andmelena. Blood tests revealed anaemia and a C-reactive proteinlevel of 90 mg/dL (normal < 5). Her CD4+ cell count wasreduced to 275 cells/µL. Physical examination showed anaxillary temperature of 39°C and mild abdominal pain.
The woman started receiving IV ciprofloxacin andmetronidazole soon after admission. A colonoscopy 3 dayslater revealed inflammatory features with aftous reactions andnecrotic regions 60cm from the anus. Histological examinationrevealed epithelial mucosal erosions, with marked chronic andacute inflammation and muscolaris mucosae involvement,suggestive of inflammatory bowel disease. She receivedmesalazine and her clinical symptoms and biochemicalparameters recovered rapidly. Over the next 3 months, sheexperienced no other symptoms of inflammatory boweldisease.Bongiovanni M, et al. Crohn’s disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. AIDS 20(Suppl.): 1989-1990, No. 15, 3 Oct 2006 - Italy 801051210
1
Reactions 18 Nov 2006 No. 11280114-9954/10/1128-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
